Review: The lysosome and neurodegenerative diseases

Acta Biochimica et Biophysica Sinica

Volumn 41, Issue 6, 2009, Pages 437-445

  Zhang, Lisha ^a   Sheng, Rui ^a   Qin, Zhenghong ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Huntington's disease; Lysosome; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

DEGENERATIVE DISEASE; HUMAN; LYSOSOME; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

HUMANS; LYSOSOMES; NEURODEGENERATIVE DISEASES;

EID: 68549111280     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmp031     Document Type: Review

References (84)

1. Nilsson C, Kagedal K, Johansson U and Ollinger K. Analysis of cytosolic and lysosomal pH in apoptotic cells by flow cytometry. Methods Cell Sci 2003, 25: 185-194.
2. Gao XC and Hu HY. Quality control of the proteins associated with neurodegenerative diseases. Acta Biochim Biophys Sin 2008, 40: 612-618.
3. Willstatter R and Bamann E. Usber die Proteased der Magen-schleimahaut. Erste Abhandlung user die Enzyme der Leukozyten. Hoppe-Sseylers Z Physiol Chem 1929, 180: 127-143.
4. Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Ann Rev Biochem 1992, 61: 307-330.
5. Lutgens SP, Cleutjens KB, Daemen MJ and Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007, 21: 3029-3041. (Pubitemid 47565524)
6. Turk B, Turk D and Turk V. Lysosomal cysteine proteases: More than scavengers. Biochem Biophys Acta 2000, 1477: 98-111.
7. Vasiljeva O and Turk B. Dual contrasting roles of cysteine cathepsins in cancer progression: Apoptosis versus tumour invasion. Biochimie 2008, 90: 380-386.
8. Felbor U, Kessler B, Mothes W, Goebel HH, Ploeggh HL, Bronson RT and Olsen BR. Neuronal loss and brain atrophy in mice lacking cathepsin B and L. Proc Natl Acad Sci USA 2002, 99: 7883-7888.
9. French LE and Tschopp J. Protein-based therapeutic approaches targeting death receptors. Cell Death Differ 2003, 10: 117-123.
10. Wei YB, Fan TJ and Yu MM. Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin 2008, 40: 278-288.
11. Deiss LP, Galinka H, Barissi H, Cohen O and Kimichi A. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-a. EMBO J 1996, 15: 3861-3870.
12. Ishisaka R, Utsumi T, Yabuki M, Kanno T, Furuno T, Inoue M and Utsumi K. Activation of caspase-3-like protease by digitonin-treated lysosomes. FEBS Lett 1998, 435: 233-236.
13. Ishisaka R, Utsumi T, Kanno T, Arita K, Katunuma N, Akiyama J and Utsumi K. Participation of a cathepsin-L-type protease in the activation of caspase-3. Cell Struct Funct 1999, 24: 465-47014
14. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C and Kaufmann SH, et al. Cathepsin B contributes to TNF-a-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000, 106: 1127-1137.
15. Roberg K, Kasgedal K and Ollinger K. Microinjection of cathepsin D induces caspase-dependent apoptosis in fibroblasts. Am J Pathol 2002, 161: 89-96.
16. Wu GS, Saftig P, Peters C and El-Deiry WS. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 1998, 16: 2177-2183.
17. Nakanishi H. Neuronal and microglial cathepsins in aging and age-related diseases. Ageing Res Rev 2003, 2: 367-381.
18. Utsumi RT, Yabuki M, Kanno T, Furuno T, Inoue M and Utsumi K. Activation of caspase-3-like protease by digitonin-treated lysosomes. FEBS Lett 1998, 435: 233-236.
19. Boya P and Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27: 6434-6451.
20. Kagedal K, Johansson AC, Johansson U, Heimlich G, Roberg K, Wang NS and Jurgensmeier JM, et al. Lysosomal membrane during apoptosis- involvement of Bax? Int J Exp Pathol 2005, 86: 309-321.
21. Shintani T and Klionsky DJ. Autophagy in health and disease: A double-edged sword. Science 2004, 5698: 990-995.
22. Blott EJ and Griffiths GM. Secretory lysosomes. Nat Rev Mol Cell Biol 2002, 3: 122-131.
23. Mizushima N. The pleiotropic role of autophagy: From protein metabolism to bactericide. Cell Death Differ 2005, 12: 1535-1541.
24. Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA and Gouras GK. Co-occurrence of Alzheimer's disease beta-amyloid and tau pathologies at synapses. Neurobiol Aging 2008 September 2 [Epub ahead of print].
25. Li M, Chen LY, Lee DHS, Yu LC and Zhang Y. The role of intracellular amyloid b in Alzheimer's disease. Prog Neurobiol 2007, 83: 131-139.
26. Chen YR and Glabe CG. Distinct early folding and aggregation properties of Alzheimer amyloid-b peptides Ab40 and Ab42. J Biol Chem 2006, 34: 24414-24422.
27. Citron M, Teplow DB and Selkoe DJ. Generation of amyloid beta protein from its precursor is sequence-specific. Neuron 1995, 14: 661-670.
28. Capell A, Steiner H, Willem M, Kaiser H, Meyer C, Walter J and Lammich S, et al. Maturation and pro-peptide cleavage of b-secretase. J Biol Chem 2000, 275: 30849-30854.
29. Vetrivel KS and Thinakaran G. Amyloidogenic processing of beta amyloid precursor protein in intracellular compartments. Neurology 2006, 66: 69-73.
30. Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, Venkataraman V and D'Andrea MR, et al. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 2007, 1142: 223-236.
31. Nixon RA, Cataldo AM and Mathews PM. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: A review. Neurochem Res 2000, 25: 1161-1172.
32. Bagnolia S, Nacmiasa B, Teddea A, Guarnierib BM, Cellinia E, Ciantellia M and Petruzzib C, et al. Cathepsin D polymorphism in Italian sporadic and familial Alzheimer's disease. Neurosci Lett 2002, 328: 273-276.
33. Bahr BA, Abai B, Gall CM, Vanderklish PW, Hoffman KB and Lynch G. Induction of b-amyloid containing polypeptides in hippocampus: Evidence for a concomitant loss of synaptic proteins and interactions with an excitotoxin. Exp Neurol 1994, 129: 1-14.
34. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J and Wang X, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer's disease. Neuron 2006, 51: 703-714.
35. Nixon RA. Autophagy, amyloidogenesis and Alzheimer's disease. J Cell Sci 2007, 120: 4081-4091.
36. Ditaranto K, Tekirian TL and Yang AJ. Lysosomal membrane damage in soluble Ab-mediated cell death in Alzheimer's disease. Neurobiol Dis 2001, 8: 19-31.
37. Xu GG, Deng YQ, Liu SJ, Li HL and Wang JZ. Prolonged Alzheimer-like Tau hyperphosphorylation induced by simultaneous inhibition of phosphoinositol-3 kinase and protein kinase C in N2a cells. Acta Biochim Biophys Sin 2005, 37: 349-354.
38. Hoffman KB, Bi XN, Pham JT and Lynch G. b-Amyloid increases cathepsin D levels in hippocampus. Neurosci Lett 1998, 250: 75-78.
39. Oyama F, Murakami N and Ihara Y. Chloroquine myopathy suggests that Tau is degraded in lysosomes: Implication for the formation of paired helical filaments in Alzheimer's disease. Neurosci Res 1998, 31: 1-8.
40. Bi XN, Haque TS, Zhou J, Skillman AG, Lin B, Lee CE and Kuntz ID. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus. J Neurochem 2000, 4: 1469-1477.
41. Hamano T, Gendron TF, Causevic E, Yen SH, Lin WL, Isidoro C and Deture M, et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci 2008, 27: 1119-1130.
42. Lim F, Hernádez F, Lucas JJ, Góez-Ramos P, Morá MA and Ávila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci 2001, 18: 702-714.
43. Ferrante RJ, Kowall NW, Beal MF, Richardson EP, Bird ED and Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985, 230: 561-563.
44. Qin ZH and Gu ZL. Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacol Sin 2004, 10: 1243-1249.
45. Lin F, Wu JC, Wang Y and Qin ZH. Huntingtin cleavage induced by thrombin in vitro. Acta Biochim Biophys Sin 2007, 39: 15-18.
46. Wellingtona CL, Ellerbyb LM, Leavittc BR, Royd S, Nicholsond DW and Haydenc MR. Huntingtin proteolysis in Huntington disease. Clin Neurosci Res 2003, 3: 129-139.
47. Dyer RB and McMurray CT. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat Genet 2001, 29: 270-278.
48. Qin ZH, Wang YM, Sapp E, Cuiffo B, Wanker E, Hayden MR and Kegel KB, et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 2004, 24: 269-281.
49. Kegel KB, Kim M, Sapp E, McIntyre C, Castano JG, Aronin N and DiFiglia M. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy. J Neurosci 2000, 20: 7268-7278.
50. Qin ZH, Wang YM, Kegel KB, Kazantsev A, Apostol BL, Thompson LM and Yoder J, et al. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet 2003, 12: 3231-3244.
51. Wu JC, Lin F and Qin ZH. Sequestration of glyceraldehyde-3- phosphate dehydrogenase to aggregates formed by mutant huntingtin. Acta Biochim Biophys Sin 2007, 39: 885-890.
52. Zhou H, Cao F, Wang Z, Yu ZX, Nguyen HP, Evans J and Li SH, et al. Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol 2003, 163: 109-118.
53. Rideout HJ, Lang-Rollin I and Stefanis L. Involvement of macroautophagy in the dissolution of neuronal inclusions. Int J Biochem Cell Biol 2004, 36: 2551-2562.
54. Ravikumar B, Duden R and Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Gen 2002, 11: 1107-1117.
55. Kunihiro U, Christiane RL, William W, Eveline S, Olaf G, Erin HN and Pham CT, et al. Convergence of heat shock protein 90 with ubiquitin in filamentous a-synuclein inclusions of a-synucleinopathies. Am J Pathol 2006, 168: 947-961.
56. Uversky VN. Neuropathology, biochemistry, and biophysics of a-synuclein aggregation. J Neurochem 2007, 103: 17-37.
57. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H and Cartwright M, et al. a-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 2005, 128: 2654-2664.
58. Hashimoto M and Masliah E. a-Synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol 1999, 9: 707-720.
59. Trojanowski JQ, Goedert M, Iwatsubo T and Lee VM. Fatal attractions: Abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ 1998, 10: 832-837.
60. Wei JS, Masayo F, Masaaki N, Masaaki W, Kazuhiko W, Hiroyasu A and Rockenstein E, et al. Enhanced lysosomal pathology caused by b-synuclein mutants linked to dementia with Lewy bodies. J Biol Chem 2007, 39: 28904-28914.
61. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M and Otero DA, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993, 90: 11282-11286.
62. Chu Y and Kordower JH. Age-associated increases of a-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis 2007, 25: 134-149.
63. Sevlever D, Jiang PZ and Yen SH. Cathepsin D Is the main lysosomal enzyme involved in the degradation of a-synuclein and generation of its C-terminally truncated species. Biochemistry 2008, 47: 9678-9687.
64. Fei XF, Qin ZH, Xiang B, Li LY, Han F, Fukunaga K and Liang ZQ. Olomoucine inhibits cathepsin L nuclear translocation, activates autophagy and attenuates toxicity of 6-hydroxydopamine. Brain Research 2009, 1264: 85-97.
65. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R and Goedert M. a-Synuclein in Lewy bodies. Nature 1997, 388: 839-840.
66. Spillantini MG, Crowther RA, Jakes R, Hasegawa M and Goedert M. a-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998, 95: 6469-6473. (Pubitemid 28249037)
67. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT and Sulzer D. Impaired degradation of mutant a-synuclein by chaperone-mediated autophagy. Science 2004, 5688: 1292-1295.
68. Stefanis L, Larsen KE, Rideout HJ, Sulzer D and Greene LA. Expression of A53T mutant but not wild-type a-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neuroscience 2001, 24: 9549-9560.
69. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A and Sagara A, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegene. Science 2000, 287: 1265-1269.
70. Hashimoto M, Rockenstein E, Mante M, Mallory M and Masliah E. b-Synuclein inhibits a-synuclein aggregation: A possible role as an anti-Parkinsonian factor. Neuron 2001, 32: 213-223.
71. Fan YX, Limprasert P, Murray IV, Smith AC, Lee VM, Trojanowski JQ and Sopher BL, et al. b-Synuclein modulates a-synuclein neurotoxicity by reducing a-synuclein protein expression. Hum Mol Genet 2006, 20: 3002-3011.
72. Uversky VN, Li J, Souillac P, Millett IS, Doniach S and Jakes R, et al. Biophysical properties of the synucleins and their propensities to fibrillate. J Biol Chem 2002, 277: 11970-11978.
73. Park JY and Lansbury PT. b-Synuclein inhibits formation of a-synuclein protofibrils: A possible therapeutic strategy against Parkinson's disease. Biochemistry 2003, 42: 3696-3700.
74. Futerman AH and van Meer G. The cell biology of lysosomal storage disorders. Nat Rev, 2004, 5: 554-565.
75. Koh CH and Cheung NS. Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: Bridging Niemann- Pick disease type C and Alzheimer's disease. Cell Signal 2006, 18: 1844-1853.
76. Mellon SH, Gong W and Schonemann MD. Endogenous and synthetic neurosteroids in treatment of Niemann-Pick Type C disease. Br Res Rev 2008, 2: 410-420.
77. Zhang JR, Coleman T, Langmade SJ, Scherrer DE, Lane L, Lanier MH and Feng C, et al. Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking. J Clin Invest 2008, 6: 2281-2290.
78. Bjurulf B, Spetalen S, Erichsen A, Vanier MT, Strom EH and Stromme P. Niemann-Pick disease type C2 presenting as fatal pulmonary alveolar lipoproteinosis: Morphological findings in lung and nervous tissue. Medical science monitor: International medical journal of experimental and clinical research 2008, 8: 71-75.
79. Liou HL, Dixit SS, Xu S, Tint GS, Stock AM and Lobel P. NPC2, the protein deficient in Niemann-Pick C2 disease, consists of multiple glycoforms that bind a variety of sterols. J Biol Chem 2006, 48: 36710-36723.
80. Ganley IG and Pfeffer SR. Cholesterol accumulation sequesters Rab9 and disrupts late endosome function in NPC1-deficient cells. J Biol Chem 2006, 281: 17890-17899.
81. Cataldo AM, Barnett JL, Pieroni C and Nixon RA. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased betaamyloidogenesis. J Neurosci 1997, 17: 6142-6151.
82. Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J and Lane W, et al. Inhibition of cathepsin B reduces b-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: Evidence for cathepsin B as a candidate b-secretase of Alzheimer's disease. J Biol Chem 2005, 386: 931-940.
83. Nixon RA. Niemann-Pick type C disease and Alzheimer's disease: The APP-endosome connection fattens up. Am J Pathol, 2004 164: 757-761.
84. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Kelleri P and Runz H, et al. Simvastatin strongly reduces levels of Alzheimer's disease b-amyloid peptides Ab42 and Ab40 in vitro and in vivo. Proc Natl Acad Sci USA 2001, 10: 5856-5861.